clinical trial · NCT05879614
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Prader-Willi SyndromeNNZ-2591
brief summary
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.
started
Sep 1, 2023
primary completion
Jun 30, 2025
completion
Jun 30, 2025
last updated
Dec 9, 2024
detailed description
The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Prader-Willi Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) doses for a total of 13 weeks.
official title
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol